Cyxone AB (publ) Share Price Nasdaq Stockholm
Equities
SE0007815428
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 25.8M 2.41M 201M |
---|---|---|---|---|---|
Net income 2024 * | -28M -2.62M -219M | Net income 2025 * | -38M -3.55M -297M | EV / Sales 2024 * | - |
Net cash position 2024 * | 1M 93.55K 7.81M | Net cash position 2025 * | 41M 3.84M 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.92
x | P/E ratio 2025 * |
-0.66
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.97% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 20/21/20 | |
Founder | 58 | 01/15/01 | |
Malin Lindskog
DFI | Director of Finance/CFO | 63 | 15/23/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 58 | 01/15/01 | |
Director/Board Member | 58 | 01/15/01 | |
Michael Oredsson
CHM | Chairman | 64 | 01/23/01 |
1st Jan change | Capi. | |
---|---|---|
+11.98% | 9.08B | |
-12.85% | 5.06B | |
+54.35% | 4.85B | |
+1.60% | 3.85B | |
+15.11% | 2.37B | |
-20.85% | 2.36B | |
+24.62% | 2.27B | |
-29.25% | 2.22B | |
-0.50% | 1.64B |